Design and Synthesis of Novel 3-triazolyl-1-thiogalactosides As Galectin-1, -3 and -8 Inhibitors

Overview

Journal RSC Adv

Publisher Royal Society of Chemistry

Specialty Chemistry

Date 2022 Jul 25

PMID 35873334

Authors

Sjors van Klaveren

Jaka Dernovsek

Ziga Jakopin

Marko Anderluh

Hakon Leffler

Ulf J Nilsson

Tihomir Tomasic

Affiliations

Soon will be listed here.

Abstract

Galectins are galactoside-binding proteins that play a role in various pathophysiological conditions, making them attractive targets in drug discovery. We have designed and synthesised a focused library of aromatic 3-triazolyl-1-thiogalactosides targeting their core site for binding of galactose and a subsite on its non-reducing side. Evaluation of their binding affinities for galectin-1, -3, and -8N identified acetamide-based compound 36 as a suitable compound for further affinity enhancement by adding groups at the reducing side of the galactose. Synthesis of its dichlorothiophenyl analogue 59 and the thiodigalactoside analogue 62 yielded promising pan-galectin inhibitors.

Citing Articles

Towards Anticancer and Antibacterial Agents: Design and Synthesis of 1,2,3-Triazol-quinobenzothiazine Derivatives.

Kisiel-Nawrot E, Pindjakova D, Latocha M, Bak A, Kozik V, Suwinska K Int J Mol Sci. 2023; 24(17).

PMID: 37686059 PMC: 10487436. DOI: 10.3390/ijms241713250.

Lactose-Functionalized Carbosilane Glycodendrimers Are Highly Potent Multivalent Ligands for Galectin-9 Binding: Increased Glycan Affinity to Galectins Correlates with Aggregation Behavior.

Mullerova M, Hovorkova M, Zavodna T, St Astna L, Krupkova A, Hamala V Biomacromolecules. 2023; 24(11):4705-4717.

PMID: 37680126 PMC: 10646984. DOI: 10.1021/acs.biomac.3c00426.

Inhibition of galectins in cancer: Biological challenges for their clinical application.

Laderach D, Compagno D Front Immunol. 2023; 13:1104625.

PMID: 36703969 PMC: 9872792. DOI: 10.3389/fimmu.2022.1104625.

References

Salameh B, Leffler H, Nilsson U . 3-(1,2,3-Triazol-1-yl)-1-thio-galactosides as small, efficient, and hydrolytically stable inhibitors of galectin-3. Bioorg Med Chem Lett. 2005; 15(14):3344-6. DOI: 10.1016/j.bmcl.2005.05.084. View

Cumpstey I, Sundin A, Leffler H, Nilsson U . C2-symmetrical thiodigalactoside bis-benzamido derivatives as high-affinity inhibitors of galectin-3: efficient lectin inhibition through double arginine-arene interactions. Angew Chem Int Ed Engl. 2005; 44(32):5110-2. DOI: 10.1002/anie.200500627. View

Cervantes-Alvarez E, Limon-de la Rosa N, Salgado-de la Mora M, Valdez-Sandoval P, Palacios-Jimenez M, Rodriguez-Alvarez F . Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients. Sci Rep. 2022; 12(1):1856. PMC: 8813958. DOI: 10.1038/s41598-022-05968-4. View

Patel B, Kishor C, Houston T, Shatz-Azoulay H, Zick Y, Vinik Y . Rational Design and Synthesis of Methyl-β-d-galactomalonyl Phenyl Esters as Potent Galectin-8 Antagonists. J Med Chem. 2020; 63(20):11573-11584. DOI: 10.1021/acs.jmedchem.0c00602. View

Cumpstey I, Salomonsson E, Sundin A, Leffler H, Nilsson U . Double affinity amplification of galectin-ligand interactions through arginine-arene interactions: synthetic, thermodynamic, and computational studies with aromatic diamido thiodigalactosides. Chemistry. 2008; 14(14):4233-45. DOI: 10.1002/chem.200701932. View

Delaine T, Collins P, MacKinnon A, Sharma G, Stegmayr J, Rajput V . Galectin-3-Binding Glycomimetics that Strongly Reduce Bleomycin-Induced Lung Fibrosis and Modulate Intracellular Glycan Recognition. Chembiochem. 2016; 17(18):1759-70. DOI: 10.1002/cbic.201600285. View

Oberg C, Noresson A, Delaine T, Larumbe A, Tejler J, Wachenfeldt H . Synthesis of 3-azido-3-deoxy-beta-D-galactopyranosides. Carbohydr Res. 2009; 344(11):1282-4. DOI: 10.1016/j.carres.2009.05.005. View

Peterson K, Collins P, Huang X, Kahl-Knutsson B, Essen S, Zetterberg F . Aromatic heterocycle galectin-1 interactions for selective single-digit nM affinity ligands. RSC Adv. 2022; 8(44):24913-24922. PMC: 9082524. DOI: 10.1039/c8ra04389b. View

Hawkins P, Skillman A, Warren G, Ellingson B, Stahl M . Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. J Chem Inf Model. 2010; 50(4):572-84. PMC: 2859685. DOI: 10.1021/ci100031x. View

10.

Hassan M, Baussiere F, Guzelj S, Sundin A, Hakansson M, Kovacic R . Structure-Guided Design of d-Galactal Derivatives with High Affinity and Selectivity for the Galectin-8 N-Terminal Domain. ACS Med Chem Lett. 2021; 12(11):1745-1752. PMC: 8592027. DOI: 10.1021/acsmedchemlett.1c00371. View

11.

Dussouy C, Kishor C, Lambert A, Lamoureux C, Blanchard H, Grandjean C . Linear triazole-linked pseudo oligogalactosides as scaffolds for galectin inhibitor development. Chem Biol Drug Des. 2020; 96(4):1123-1133. DOI: 10.1111/cbdd.13683. View

12.

Pal K, Mahanti M, Huang X, Persson S, Sundin A, Zetterberg F . Quinoline-galactose hybrids bind selectively with high affinity to a galectin-8 N-terminal domain. Org Biomol Chem. 2018; 16(34):6295-6305. DOI: 10.1039/c8ob01354c. View

13.

Chien C, Ho M, Lin C, Hsu S . Lactose Binding Induces Opposing Dynamics Changes in Human Galectins Revealed by NMR-Based Hydrogen-Deuterium Exchange. Molecules. 2017; 22(8). PMC: 6152064. DOI: 10.3390/molecules22081357. View

14.

Barake F, Soza A, Gonzalez A . Galectins in the brain: advances in neuroinflammation, neuroprotection and therapeutic opportunities. Curr Opin Neurol. 2020; 33(3):381-390. DOI: 10.1097/WCO.0000000000000812. View

15.

Humphrey W, Dalke A, Schulten K . VMD: visual molecular dynamics. J Mol Graph. 1996; 14(1):33-8, 27-8. DOI: 10.1016/0263-7855(96)00018-5. View

16.

MacKerell Jr A, Feig M, Brooks 3rd C . Extending the treatment of backbone energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J Comput Chem. 2004; 25(11):1400-15. DOI: 10.1002/jcc.20065. View

17.

Wolber G, Langer T . LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model. 2005; 45(1):160-9. DOI: 10.1021/ci049885e. View

18.

Sethi A, Sanam S, Alvala R, Alvala M . An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016-present). Expert Opin Ther Pat. 2021; 31(8):709-721. DOI: 10.1080/13543776.2021.1903430. View

19.

Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, Zhong S, Shim J . CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J Comput Chem. 2009; 31(4):671-90. PMC: 2888302. DOI: 10.1002/jcc.21367. View

20.

Hsieh T, Lin H, Tu Z, Lin T, Wu S, Tseng Y . Dual thio-digalactoside-binding modes of human galectins as the structural basis for the design of potent and selective inhibitors. Sci Rep. 2016; 6:29457. PMC: 4945863. DOI: 10.1038/srep29457. View